Enclomiphene Citrate: What It Is and What It Does

What Enclomiphene Citrate is

Enclomiphene citrate is the trans-isomer of clomiphene citrate, a non-steroidal selective estrogen receptor modulator (SERM). Unlike a peptide it is a small molecule taken orally. It is supplied as an analytical-grade reference material in capsule form for laboratory research.

Where it comes from

Clomiphene citrate, in use since the 1960s, was never one molecule. It is a mixture of two isomers that behave very differently. Zuclomiphene, the cis form, is estrogenic and lingers in the body for weeks. Enclomiphene, the trans form, is the anti-estrogenic half and clears far faster. In the 2000s researchers separated the two and developed enclomiphene on its own, on the reasoning that the useful activity and the long-lived estrogenic baggage could be pulled apart. It was carried through phase II and phase III trials in the 2010s under the development name Androxal.

What it does — in plain terms

The body decides how much testosterone to make using a feedback loop: the testes produce testosterone, some of it converts to estrogen, and estrogen tells the pituitary gland to ease off. Enclomiphene sits on the estrogen receptors in that part of the brain and blocks the message. The pituitary reads this as not enough yet and keeps sending the signalling hormones LH and FSH, so the testes keep working. That is the key difference from supplying testosterone directly, which does the opposite: it satisfies the feedback loop, the brain stops signalling, and sperm production falls as a result.

How it works

Enclomiphene is a competitive antagonist at estrogen receptors in the hypothalamus and pituitary. Estrogen normally provides the negative feedback that throttles gonadotropin output; with the receptor occupied, that brake is lifted and the pituitary continues releasing luteinizing hormone and follicle-stimulating hormone.

Because the resulting testosterone is produced by the testes rather than supplied from outside, the intratesticular environment that supports spermatogenesis is left intact. This is the mechanistic reason the trials tracked sperm concentration alongside serum testosterone, and it is the property that separates enclomiphene from exogenous androgen in the published comparisons.

Separating the isomers matters pharmacokinetically as well. Zuclomiphene has a long half-life and estrogen-agonist character, so it accumulates with repeated dosing of the racemic mixture; enclomiphene alone clears more quickly. Reported effects were dose-dependent and measured over defined trial periods, so extrapolating beyond those windows is not supported by the data.

What the research shows

Enclomiphene has an unusually specific evidence base for a compound in this catalog: several registered clinical trials in men, with hormone and semen measurements taken directly rather than inferred. It is equally important to be straight about the ceiling on that evidence. Despite completing phase III work it did not obtain FDA approval, long-term outcome data are limited, and most published work comes from a small number of related trial programmes. What follows describes what those studies measured, not what the compound will do for any individual.

• Fertility and Sterility, 2014 — A randomized phase II trial reported that enclomiphene citrate raised serum total testosterone in men with secondary hypogonadism while sperm concentration was maintained, in contrast to the decline associated with exogenous testosterone.
• BJU International, 2016 — A phase III trial in obese men with hypogonadism found that oral enclomiphene raised serum testosterone and preserved sperm counts, whereas topical testosterone raised testosterone but was associated with reduced sperm counts.
• The Journal of Sexual Medicine, 2013 — An earlier comparative study reported that oral enclomiphene stimulated endogenous testosterone production and supported sperm counts in men with low testosterone.
• BJU International, 2013 — A pharmacodynamic and pharmacokinetic study characterised how enclomiphene restored testosterone in men with secondary hypogonadism, describing the dose-response relationship and clearance behaviour of the isolated trans-isomer.
• Andrology, 2023 — A systematic review and meta-analysis of selective estrogen receptor modulation in obese men with androgen deficiency pooled the available trials and examined how consistent the hormonal response was across them.
• Translational Andrology and Urology, 2024 — A comparative review examined the safety and efficacy signals reported for enclomiphene alongside clomiphene in hypogonadal men, and noted where the evidence for each remains incomplete.

What Enclomiphene Citrate is studied for

Endogenous testosterone production. Trials measured serum total testosterone as a primary endpoint, with the compound acting on the pituitary signal rather than supplying androgen from outside the body.

Preservation of spermatogenesis. Sperm concentration was tracked alongside hormone levels precisely because exogenous testosterone is known to suppress it; this contrast is the most consistently reported finding in the literature.

Secondary hypogonadism with obesity. Much of the phase II and III work enrolled men with obesity-associated secondary hypogonadism, where increased conversion of testosterone to estrogen strengthens the very feedback signal being blocked.

Isomer pharmacology. Separate work compared serum levels of enclomiphene and zuclomiphene during long-term clomiphene use, which is the basis for studying the trans-isomer on its own rather than the racemic mixture.

Storage & handling

Supplied as oral capsules, so unlike the lyophilized peptides in this catalog there is no reconstitution step, no diluent and no freeze-thaw consideration. Keep the container sealed, cool, dry and out of direct light; moisture is the main practical concern for a capsule format.